Back

Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 5 - Bleeding and LAA occlusion Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Mr Jeffrey Trocio

New York (United States of America)

8 More presentations in this session

Presentation thumbnail
Establishment and assessment of an LAA occlusion preoperative simulation system based on 3D Printing of 3DTEE imaging
Professor R. Guo (Wuhan, CN)
Presentation thumbnail
Predictors of cardiovascular events in patients with atrial fibrillation after left atrial appendage closure for stroke prevention in a multicenter analysis.
Professor L. Fauchier (Tours, FR)
Abstract Slides
Presentation thumbnail
A comparative study of 3d reconstruction of left atrial appendage model based on ultrasound and CT 3d DICOMdata
Professor R. Guo (Wuhan, CN)
Presentation thumbnail
Long-term evaluation of safety and efficiency of left atrial appendage (LAA) occlusion
Doctor V. Lekesova (Prague, CZ)
Abstract Slides
Presentation thumbnail
Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy
Miss M. Yee (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Poster session 5 - Bleeding and LAA occlusion

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources